Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AAPL | 6.4% revenue growth vs INBX's -88.9% |
| Value | INBX | Lower P/E (0.6x vs 31.1x) |
| Quality / Margins | AAPL | 27.0% net margin vs INBX's -110.8% |
| Stability / Safety | INBX | Beta 0.74 vs AAPL's 1.28, lower leverage |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; INBX pays no meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs AAPL's +9.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs INBX's -87.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). INBX leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
AAPL is the larger business by revenue, generating $435.6B annually — 311155.0x INBX's $1M. AAPL is the more profitable business, keeping 27.0% of every revenue dollar as net income compared to INBX's -110.8%.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $435.6B |
| EBITDAEarnings before interest/tax | -$151M | $152.9B |
| Net IncomeAfter-tax profit | -$155M | $117.8B |
| Free Cash FlowCash after capex | -$143M | $123.3B |
| Gross MarginGross profit ÷ Revenue | -86.3% | +47.3% |
| Operating MarginEBIT ÷ Revenue | -110.0% | +32.4% |
| Net MarginNet income ÷ Revenue | -110.8% | +27.0% |
| FCF MarginFCF ÷ Revenue | -102.5% | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +18.3% |
Valuation Metrics
At 0.6x trailing earnings, INBX trades at a 98% valuation discount to AAPL's 35.4x P/E.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $1.1B | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $930M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | — | 27.45x |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | 9.33x |
| Price / BookPrice ÷ Book value/share | 8.03x | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $-4 for INBX. INBX carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to AAPL's 1.67x. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs INBX's 4/9, reflecting strong financial health.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | +133.5% |
| ROA (TTM)Return on assets | -87.4% | +31.1% |
| ROICReturn on invested capital | — | +64.5% |
| ROCEReturn on capital employed | -169.3% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 1.67x |
| Net DebtTotal debt minus cash | -$145M | $89.7B |
| Cash & Equiv.Liquid assets | $153M | $33.5B |
| Total DebtShort + long-term debt | $8M | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | — |
Total Returns (with DRIP)
A $10,000 investment in INBX five years ago would be worth $25,954 today (with dividends reinvested), compared to $21,049 for AAPL. Over the past 12 months, INBX leads with a +459.5% total return vs AAPL's +9.7%. The 3-year compound annual growth rate (CAGR) favors INBX at 46.1% vs AAPL's 21.9% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | -2.4% |
| 1-Year ReturnPast 12 months | +459.5% | +9.7% |
| 3-Year ReturnCumulative with dividends | +211.6% | +81.2% |
| 5-Year ReturnCumulative with dividends | +159.5% | +110.5% |
| 10-Year ReturnCumulative with dividends | +263.5% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +21.9% |
Risk & Volatility
INBX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs INBX's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 1.28x |
| 52-Week HighHighest price in past year | $94.56 | $288.61 |
| 52-Week LowLowest price in past year | $10.81 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 165K | 40.9M |
Analyst Outlook
Wall Street rates INBX as "Buy" and AAPL as "Buy". AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | INBXInhibrx Bioscienc… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $303.11 |
| # AnalystsCovering analysts | 5 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| Apple Inc. (AAPL) | 100 | 201.23 | +101.2% |
Inhibrx Biosciences… (INBX) returned +160% over 5 years vs Apple Inc. (AAPL)'s +110%. A $10,000 investment in INBX 5 years ago would be worth $25,954 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
INBX vs AAPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is INBX or AAPL a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INBX or AAPL?
On trailing P/E, Inhibrx Biosciences, Inc. (INBX) is the cheapest at 0.6x versus Apple Inc. at 35.4x.
03Which is the better long-term investment — INBX or AAPL?
Over the past 5 years, Inhibrx Biosciences, Inc. (INBX) delivered a total return of +159.5%, compared to +110.5% for Apple Inc. (AAPL). A $10,000 investment in INBX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus INBX's +263.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INBX or AAPL?
By beta (market sensitivity over 5 years), Inhibrx Biosciences, Inc. (INBX) is the lower-risk stock at 0.74β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 73% more volatile than INBX relative to the S&P 500. On balance sheet safety, Inhibrx Biosciences, Inc. (INBX) carries a lower debt/equity ratio of 6% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — INBX or AAPL?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus 26.9% for Apple Inc. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus -1657.2% for INBX. At the gross margin level — before operating expenses — AAPL leads at 46.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — INBX or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. INBX does not pay a meaningful dividend and should not be held primarily for income.
07Is INBX or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Apple Inc. (AAPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.28), +1027% 10Y return). Both have compounded well over 10 years (AAPL: +1027%, INBX: +263.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between INBX and AAPL?
These companies operate in different sectors (INBX (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. In terms of investment character: INBX is a small-cap deep-value stock; AAPL is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.